Global High Content Screening Market 2022-2028
According to market research study published by Gen Consulting Company, the global high content screening market stood at around USD 1,105 million in 2021 and is projected to rise to a worth of USD 2,046 million by 2028 end, thereby garnering a CAGR of 9.2% during 2022-2028.
The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global high content screening market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the high content screening industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the component, application, end user, and region. The global market for high content screening can be segmented by component: consumables (reagents and kits), instrument or platform, services, software and analytics. The instrument or platform segment held the largest revenue share in 2021. High content screening market is further segmented by application: compound profiling, drug discovery, molecular diagnosis, oncology, toxicity studies, others. Among these, the drug discovery segment was accounted for the highest revenue generator in 2021. Based on end user, the high content screening market is segmented into: academic institutions, laboratories and pathology centers, pharmaceutical and biotechnology companies. The pharmaceutical and biotechnology companies segment captured the largest share of the market in 2021. On the basis of region, the high content screening market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).
By component:
- consumables (reagents and kits)
- instrument or platform
- services
- software and analytics
By application:
- compound profiling
- drug discovery
- molecular diagnosis
- oncology
- toxicity studies
- others
By end user:
- academic institutions
- laboratories and pathology centers
- pharmaceutical and biotechnology companies
By region:
- Asia Pacific
- Europe
- North America
- Rest of the World (RoW)
The instrument market is further segmented into cytometers, detectors and sensors, imaging devices, liquid handling instruments, plate readers, others. Globally, the imaging devices segment made up the largest share of the high content screening market.
The report has also analysed the competitive landscape of the global high content screening market with some of the key players being Agilent Technologies Inc., Bio-Rad Laboratories, Inc., Danaher Corp., GE Healthcare, Merck KGaA, Olympus Corporation, PerkinElmer, Inc., Sartorius AG, Thermo Fisher Scientific Inc., Yokogawa Electric Corporation, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.
Scope of the Report
- To analyze and forecast the market size of the global high content screening market.
- To classify and forecast the global high content screening market based on component, application, end user, region.
- To identify drivers and challenges for the global high content screening market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global high content screening market.
- To identify and analyze the profile of leading players operating in the global high content screening market.
Why Choose This Report
- Gain a reliable outlook of the global high content screening market forecasts from 2022 to 2028 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.